Overview

Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of ticagrelor and clopidogrel on endothelial dysfunction and vascular inflammation Ticagrelor will lead to beneficial pleiotropic effects compared with treatment with clopidogrel in patients receiving a drug-eluting stents (DES) during percutaneous coronary intervention (PCI) for non-ST-segment acute coronary syndrome (NSTE-ACS) beyond 1 month after the index event. Ticagrelor treatment will improve percent flow-mediated dilation (FMD) values and reduces inflammatory gene expression on peripheral blood mononuclear cells.
Phase:
Phase 4
Details
Lead Sponsor:
Kiyuk Chang
Collaborator:
AstraZeneca
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine